8-K: DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation announced that the FDA has granted Breakthrough Therapy designation to larsucosterol for the treatment of severe alcohol-associated hepatitis.

Summary

• DURECT Corporation has received Breakthrough Therapy designation from the FDA for larsucosterol, a drug being developed to treat severe alcohol-associated hepatitis (AH).
• This designation is based on promising data from the Phase 2b AHFIRM trial, which evaluated the safety and efficacy of larsucosterol.
• The AHFIRM trial included 307 patients across multiple sites in the U.S., EU, U.K., and Australia, comparing larsucosterol at 30mg and 90mg doses against a placebo.
• The primary outcome of the AHFIRM trial was the 90-day incidence of mortality or liver transplantation, with a key secondary endpoint of 90-day survival.
• AH is a severe form of liver disease with high mortality rates and no currently approved treatments, with mortality rates of 26% at 28 days, 29% at 90 days and 44% at 180 days in a retrospective analysis of 77 studies.
• A subsequent global study reported mortality at 28 and 90 days of approximately 20% and 31%, respectively.
• The Breakthrough Therapy designation aims to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions.
• DURECT is planning a Phase 3 clinical trial to further confirm the efficacy and safety of larsucosterol.

Sentiment

Score: 8

Explanation: The document is very positive due to the FDA's Breakthrough Therapy designation, which significantly increases the likelihood of the drug's approval and market success. The unmet need in the treatment of AH also adds to the positive sentiment.

Positives

• The FDA's Breakthrough Therapy designation for larsucosterol indicates the potential of the drug to address a critical unmet medical need.
• The Phase 2b AHFIRM trial showed promising data supporting the efficacy of larsucosterol.
• The Breakthrough Therapy designation may expedite the development and approval process for larsucosterol.
• Larsucosterol targets a novel mechanism of action as an epigenetic modulator, potentially offering a new approach to treating AH.
• There are currently no FDA-approved treatments for AH, making larsucosterol a potential first-in-class therapy.

Negatives

• The document notes that the Breakthrough Therapy designation does not guarantee FDA approval.
• The company acknowledges that future clinical trials may not confirm the results of the AHFIRM trial.
• The company is still in the process of finalizing the design of the Phase 3 trial.
• The company faces risks related to the sufficiency of cash resources and the need for additional financing.

Risks

• Future clinical trials of larsucosterol may be delayed or may not confirm the results from the AHFIRM trial.
• The FDA may require additional clinical trials before approving larsucosterol.
• The Breakthrough Therapy designation does not guarantee expedited FDA approval.
• DURECT faces risks related to its cash resources and ability to obtain additional financing.
• The company's ability to continue to meet the minimum bid price for continued listing on Nasdaq is a risk.

Future Outlook

DURECT plans to conduct a Phase 3 clinical trial to confirm the efficacy and safety of larsucosterol and potentially bring this therapy to patients as soon as possible.

Management Comments

• James E. Brown, D.V.M., President and CEO of DURECT, stated that the FDA's decision to grant Breakthrough Therapy designation to larsucosterol recognizes its potential to save the lives of AH patients.
• He also noted the high mortality rate of AH and the lack of currently approved treatments, emphasizing the need for a safe and effective therapy.

Industry Context

The announcement is significant as there are currently no FDA-approved treatments for alcohol-associated hepatitis, a condition with high mortality rates. The Breakthrough Therapy designation highlights the potential of larsucosterol to address this unmet medical need and could position DURECT as a leader in this therapeutic area.

Comparison to Industry Standards

• The lack of approved therapies for AH makes larsucosterol a potential first-in-class treatment, setting it apart from existing options.
• The mortality rates cited for AH (26% at 28 days, 29% at 90 days, and 44% at 180 days in a retrospective analysis) highlight the severity of the condition and the need for effective treatments.
• The global study reporting mortality at 28 and 90 days of approximately 20% and 31%, respectively, further underscores the urgency for new therapies.
• Current treatments, such as corticosteroids, are limited by contraindications and have not shown to improve survival at 90 days or one year, making larsucosterol's potential impact significant.

Stakeholder Impact

• Shareholders may view the Breakthrough Therapy designation positively, potentially leading to an increase in stock value.
• Patients with severe alcohol-associated hepatitis stand to benefit from a potential new treatment option.
• Employees of DURECT may experience increased job security and opportunities due to the progress of larsucosterol.
• The medical community may see this as a significant step forward in the treatment of a challenging condition.

Next Steps

• DURECT plans to finalize the design of its Phase 3 clinical trial for larsucosterol.
• The company will release additional clinical data on larsucosterol at the EASL Congress 2024 on June 8, 2024.
• DURECT aims to potentially bring larsucosterol to patients as soon as possible.

Key Dates

Keywords

larsucosterol, alcohol-associated hepatitis, breakthrough therapy designation, FDA, AHFIRM trial, epigenetic therapy, DURECT, clinical trial, liver disease, DNMT inhibitors